No connection

Search Results

Analysis Neutral

Mesoblast drops after Ryoncil sales data for March quarter

Apr 07, 2026 15:13 UTC

Mesoblast drops after Ryoncil sales data for March quarter.

  • anilakkus/iStock via Getty Images Mesoblast (MESO) ADRs fell on Tuesday as investors reacted to sales data the Australian company reported for its cell therapy Ryoncil for the quarter ending Mar
  • 31, 2026
  • The treatment approved by the FDA in December 2024 for acute graft-versus-host

anilakkus/iStock via Getty Images Mesoblast (MESO) ADRs fell on Tuesday as investors reacted to sales data the Australian company reported for its cell therapy Ryoncil for the quarter ending Mar. 31, 2026. The treatment approved by the FDA in December 2024 for acute graft-versus-host

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile